Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats

Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as...

Full description

Saved in:
Bibliographic Details
Main Authors: Liping Wei, Min Hong, Min Lu, Yimin Qian, Qingmei Li, Naping Tang, Hua Li, Yan Chang, Yunliang Qiu
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-05-01
Series:Drugs in R&D
Online Access:https://doi.org/10.1007/s40268-025-00504-x
Tags: Add Tag
No Tags, Be the first to tag this record!